

## ThermoFMN - A Thermofluor Assay Developed for Ligand-Screening as an Alternative Strategy for Drug Discovery

*Ricardo A. P. Pádua, Giovani P. Tomaleri, Renata A. G. Reis, Juliana S. David, Valeria C. Silva, Matheus P. Pinheiro and Maria Cristina Nonato\**

*Laboratório de Cristalografia de Proteínas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Av. Café S/N, Monte Alegre, 14040-903 Ribeirão Preto-SP, Brazil*

A técnica de Thermofluor constitui uma importante ferramenta na identificação de moléculas protótipos a fármacos. No presente trabalho, foi desenvolvido um método alternativo para a técnica de Thermofluor, chamado ThermoFMN, que explora o grupo prostético flavina mononucleotídeo (FMN) como sonda fluorescente. A validação do método foi feita através do monitoramento da fluorescência do FMN para diferentes alvos macromoleculares na presença de uma biblioteca aleatória de ligantes. Além disso, fármacos com eficácia comprovada tiveram seus perfis de inibição seletiva avaliados. Além de demonstrar que o rendimento quântico do FMN fornece intensidade adequada para detecção, nossos resultados revelam que o método de ThermoFMN utiliza-se de baixas concentrações de proteína e é compatível com uma vasta quantidade de tampões e aditivos químicos. A metodologia apresentada nesse trabalho propõe uma estratégia alternativa na busca por ligantes para proteínas dependentes de FMN, como uma importante ferramenta no desenvolvimento de novas terapias contra doenças negligenciadas.

Thermofluor has become a well-known and widely practiced methodology for screening of ligands that enhance stability and solubility of proteins, and also a powerful tool for hit identification in early drug discovery. In the present work, we developed an alternative Thermofluor method, named ThermoFMN, which explores the endogenous prosthetic group flavin mononucleotide (FMN) of flavoproteins as the fluorescent probe. Validation of ThermoFMN method was achieved by monitoring fluorescence signal of FMN of several drug targets in the presence of an unbiased library of ligands. In addition, drugs with known efficacy had their selective inhibition profile evaluated. Besides demonstrating that FMN signal provides sufficient fluorescence intensity for detection, our results revealed that ThermoFMN assay requires low concentration of protein samples and is compatible with a wide range of chemical reagents. The methodology presented here proposes an alternative strategy in the search for ligands of FMN-binding drug targets, therefore an important tool for the development of new therapies against neglected diseases.

**Keywords:** FMN, Thermofluor, drug targets, ThermoFMN, drug discovery, dihydroorotate dehydrogenase

### Introduction

The term neglected diseases refers to a group of tropical infections which used to be endemic to specific low-income populations in developing regions of Africa, Asia and the Americas. However, the latest statistical data available indicate that this reality has changed and many of those diseases have spread to new areas of the world, striking regions once thought safe, increasing the number of infected people and giving rise to greater genetic

diversity in terms of their related pathogens.<sup>1</sup> This new demographic distribution together with inadequate public health infrastructure and lack of investment from both public and private health sectors constitute large barriers to be overcome when searching for effective strategies to treat, control and eradicate this group of poverty-promoting chronic infectious diseases.<sup>2</sup>

Innovation in drug research has been traditionally considered as a responsibility of pharmaceutical companies, with little or none direct contribution from the Academia. The high cost and the problem-driven multidisciplinary approach involved in the pipeline of drug discovery have

\*e-mail: cristy@fcfrp.usp.br

hampered a major role of the Academia in the process of drug development, and run contrary to the free-thinking basic research, thought and developed in the academic environment.

However, when it comes to neglected diseases, the research developed at the university, especially for those located in endemic countries like Brazil, is expected to contribute to change these devastating public health scenario.

For example, drug discovery for neglected diseases is carried out using both target-based and phenotypic approaches.<sup>3</sup> Target-based drug discovery has been largely used in the pharmaceutical industry, but careful selection of targets is still required.<sup>4</sup> Unfortunately, there are still very few fully validated drug targets in the vast field of neglected diseases, i.e., where there is a registered drug for which the elucidated mode of action depends on the inhibition/activation of the proposed target. Thus, academic concentrated efforts are still necessary for the identification, characterization and validation of new drug targets.

In addition, target-based drug discovery involves screening libraries of compounds, *in silico* and *in vitro*, and further optimization of lead compounds in order to achieve better potency, selectivity and pharmacological properties. As such, the development and/or improvement of techniques for target-based ligand screening are of extreme importance.

As an example, the fluorescence-based thermal stability assay (Thermofluor), originally developed by Pantoliano and coworkers in 2001, has nowadays become a well-known and widely practiced methodology for screening of ligands.<sup>5</sup> Thermofluor monitors ligand effects on temperature-dependent protein unfolding. Besides vastly used for ligand screening in modern drug discovery, by screening factors such as pH, buffer type, ionic strength and random solubilizing agents, Thermofluor also plays an important role in the identification of ideal chemical environment to enhance stability and solubility of proteins, allowing better conditions for sample manipulation, characterization and storage.<sup>6,7</sup>

The probes commonly used in the Thermofluor assay give rise to a fluorescence signal when binding to exposed hydrophobic areas of unfolded proteins. Probes such as Nile red, 1,8-ANS, bis-ANS exploit hydrophobic and electrostatic interactions with proteins and display characteristic excitation and emission spectra.<sup>8</sup> In particular, the most popular dye for thermal shift assays is SYPRO Orange with an excitation at 492 nm and fluorescence emission at 610 nm, after binding to protein hydrophobic patches.

A major limitation for the use of this methodology, due to the use of hydrophobic fluorophores, is their incompatibility with detergents, very needed to avoid both ligand and protein aggregation. Thus, alternative strategies have been developed to allow the use of Thermofluor techniques. For example, the screening of optimal buffers and detergents for purified membrane proteins can be performed by using the thiol-specific fluorochrome *N*-[4-(7-diethylamino-4-methyl-3-coumarinyl)phenyl]maleimide (CPM). This screen uses the chemical reactivity of the native cysteines embedded in the protein interior as a sensor for the overall integrity of the folded state.<sup>9</sup> In addition, alternative dye-free methods have also been proposed to allow the use of thermofluor methodology. For example, Warne *et al.* reported the development of microscale assay to measure the thermal stability of a membrane protein depending on <sup>3</sup>H labeled ligand binding.<sup>10</sup> Also, Forneris *et al.* demonstrated that flavin adenine dinucleotide (FAD) can be used as a probe to monitor protein unfolding.<sup>11</sup>

In the present work, we present an alternative dye-free method for Thermofluor (differential scanning fluorimetry), named ThermoFMN, which explores the endogenous prosthetic group FMN of flavoenzymes as a fluorescent probe. Flavoenzymes are involved in a wide range of biological processes including energy production, biodegradation, chromatin remodeling, DNA repair, apoptosis, protein folding, detoxification, neural development and biosynthesis and thus represent an important group of potential drug targets.<sup>12</sup>

The efficacy of our method was validated by testing a wide range of ligands against potential macromolecular targets for drug development including *Leishmania major* dihydroorotate dehydrogenase (LmDHODH), *Trypanosoma cruzi* dihydroorotate dehydrogenase (TcDHODH), all targets for the development of trypanosomatid-related diseases,<sup>13</sup> and human dihydroorotate dehydrogenase (HsDHODH), which besides used in cross-validation assays, also constitutes a validated target for the treatment of proliferative, autoimmune and inflammatory diseases.<sup>14</sup>

Our results show that FMN quantum yield observed within the range of temperature tested and under a broad spectrum of chemical compounds provides sufficient fluorescence intensity to determine the melting temperatures of FMN-binding proteins. ThermoFMN assay proved to be a useful tool for screening of selective ligands that enhance stability and solubility of protein targets, as well as for hit identification in early drug discovery.

Our findings represent a contribution for ligand screening in general and also bring important contribution for our research dedicated to the development of new therapeutics to fight neglected diseases.

## Experimental

### Chemicals and materials

All buffers and salts used were HPLC grade and were acquired from J. T. Baker and Sigma. Solubility & Stability Screen was acquired from Hampton Research (HR2-072).

### Protein Production

*Leishmania major* DHODH and *Trypanosoma cruzi* DHODH have been expressed and purified as previously described.<sup>15,16</sup> For the cross-validation experiments, human DHODH (HsDHODH) was subcloned into pET-28a expression vector (Novagen). A pet22-b construct encoding HsDHODH was kindly provided by Prof Jon Clardy from Harvard Medical School and used as a template. HsDHODH was digested with *NdeI/XhoI* restriction enzymes and the digestion product was purified using the QIAquick Gel Extraction Kit (Qiagen). The purified 1104 bp fragment was ligated into the pET-28a(+) vector, previously linearized with the same restriction enzymes to form a pET-28a(+)-HsDHODH construct. This construction produces human DHODH as an *N*-terminal and *C*-terminal six-histidine fusion protein. The ligated mixture was first transformed into *E. coli* DH5 $\alpha$  for plasmid propagation. Plasmid DNA was extracted using Wizard Plus SV Minipreps (Promega). Sequence of the cloned gene was confirmed by DNA sequencing. The expression plasmid was then transformed into *E. coli* BL21(DE3) for protein production. Thus, a single colony of *E. coli* BL21(DE3) cells harboring the pET-28a(+)-HsDHODH plasmid was inoculated into 20 mL Luria-Bertani broth (LB) supplemented with 30  $\mu\text{g mL}^{-1}$  kanamycin at 37 °C overnight with shaking (250 rpm).

The overnight culture was then diluted to 1:100 with LB containing 30  $\mu\text{g mL}^{-1}$  kanamycin and grew at 37 °C till OD<sub>600</sub> reached 0.5-0.6. The cells were induced by the addition of 0.5 mmol L<sup>-1</sup> isopropyl  $\beta$ -D-thiogalactopyranoside (IPTG) for 6 h at 25 °C with shaking (250 rpm). Finally, the cells were harvested by centrifugation at 7,000 g for 10 min at 4 °C. A cell pellet from 2 L of culture was lysed in 15 mL of lysis buffer (50 mmol L<sup>-1</sup> sodium phosphate, pH 8, 300 mmol L<sup>-1</sup> NaCl, 10 mmol L<sup>-1</sup> imidazole, 1% Triton X-100 and 1 mmol L<sup>-1</sup> phenylmethylsulfonyl fluoride (PMSF)). The cells were further disrupted by sonication at 15  $\times$  30 s bursts (with 30 s intervals between each burst) on ice. After 30 min of stirring at 4 °C, the insoluble debris were separated by centrifugation at 16,100 g for 30 min at 4 °C. The clear supernatant containing HsDHODH was loaded on a 1 mL column Ni-NTA agarose affinity resin

(Qiagen) equilibrated with 50 mmol L<sup>-1</sup> sodium phosphate, pH 8, buffer containing 300 mmol L<sup>-1</sup> NaCl, 10 mmol L<sup>-1</sup> imidazole and 0.1% Triton X-100. The column was then washed with a step gradient of imidazole from 10 to 50 mmol L<sup>-1</sup> in equilibration buffer (50 mmol L<sup>-1</sup> sodium phosphate, pH 8, 300 mmol L<sup>-1</sup> NaCl plus imidazole). The washes consisted of 50 column volumes of equilibration buffer in 10 mmol L<sup>-1</sup> imidazole, followed by 50 column volumes in 25 mmol L<sup>-1</sup> imidazole, and 50 column volumes in 50 mmol L<sup>-1</sup> imidazole. The target protein was eluted with 30 column volumes of the equilibration buffer containing 250 mmol L<sup>-1</sup> imidazole. The yield of pure HsDHODH was typically 3.5 mg L<sup>-1</sup> of culture.

### Protein extinction coefficient

The concentration of the enzyme targets was estimated based on their molar extinction coefficient. Initially, 500  $\mu\text{L}$  of pure protein samples were scanned within the visible region of the spectrum and the maximum absorbance found around 450 nm recorded ( $Abs_{max_{enz}}$ ). The scanned samples were then heated to 80 °C for 5 min followed by centrifugation at 16,100 g for 10 min. The yellow supernatant containing free FMN was separated from the insoluble fraction, scanned, and the maximum absorbance at 450 nm recorded. The enzyme extinction coefficient was determined considering equimolar concentrations of free and enzyme-bound FMN (equation 1). The FMN extinction coefficient of  $\epsilon_{FMN} = 12,500 \text{ mol}^{-1} \text{ L cm}^{-1}$  was used as reference:

$$\epsilon_{enz} = \frac{Abs_{max_{enz}} \times \epsilon_{FMN}}{Abs_{450nm_{FMN}}} \quad (1)$$

### ThermoFMN assay

Protein melting temperature ( $T_m$ ) determination was performed by monitoring protein unfolding using FMN as the fluorescent probe. ThermoFMN monitors the fluorescent signal of FMN upon its releasing from the protein target as a function of temperature. ThermoFMN assay was performed on Agilent Mx3005P QPCR System equipped with a FAM SYBr green I filter with excitation and emission wavelengths of 492 nm and 516 nm, respectively.

For the thermal stability assay each condition tested required an aliquot of 10  $\mu\text{L}$  from 10  $\mu\text{mol L}^{-1}$  stock of purified protein mixed with 10  $\mu\text{L}$  of different screening solutions in 96-well plates sealed with optical quality sealing tape (Microseal® 'B' seal from BIO-RAD). Plates were centrifuged for 2 min at 200 g immediately before the assay to remove possible air bubbles. For the thermal

denaturation the plates were heated from 25 to 95 °C with stepwise increments of 1 °C and a 1 min hold step for every point, followed by the fluorescence reading.

Considering that the experimental volume is fixed, two parameters may influence the signal strength: the FMN concentration and the mechanism of interaction between protein and FMN. Thus, in order to optimize the fluorescence signal-to-noise ratio, an initial assay was performed by monitoring the fluorescence signal at different concentrations of free FMN (25  $\mu\text{mol L}^{-1}$ , 12.5  $\mu\text{mol L}^{-1}$ , 6.25  $\mu\text{mol L}^{-1}$ , 3.125  $\mu\text{mol L}^{-1}$ , 1.5625  $\mu\text{mol L}^{-1}$ , 0.78125  $\mu\text{mol L}^{-1}$ , 0.290625  $\mu\text{mol L}^{-1}$  and 0.195325  $\mu\text{mol L}^{-1}$ ). The reference experiment for determining the size of the noise was performed by monitoring the fluorescence signal of water-containing wells. A signal-to-noise ratio of two was obtained using 5  $\mu\text{mol L}^{-1}$  FMN final concentration (Figure S1). This concentration was then used as reference for TcDHODH, LmDHODH and HsDHODH protein samples, for the remaining of this work.

Thus, previously to ThermoFMN experiment, TcDHODH, LmDHODH and HsDHODH were dialyzed against 50  $\text{mmol L}^{-1}$  HEPES pH 7.2, 150  $\text{mmol L}^{-1}$  NaCl and concentrated to 10  $\mu\text{mol L}^{-1}$  based on the molar extinction coefficient. The commercially available Solubility & Stability Screen (Hampton Research) was used for evaluating the effects of different buffer and chemical additives on both quantum yield and protein melting temperatures during ThermoFMN assay. The control experiment was prepared by adding the protein buffer instead of the additive compound. In addition, the effects of known DHODH inhibitors (A77 1726, brequinar) on protein unfolding were tested at 40  $\mu\text{mol L}^{-1}$  final concentration. The control experiment was prepared by adding DMSO instead of the ligand.

The fluorescence data were processed according to the procedure described by Niesen *et al.*<sup>17</sup>

## Results and Discussion

In the present work we developed the ThermoFMN assay, a methodology dedicated to evaluate ligand effects on thermostability of FMN-binding proteins. By monitoring the environment-sensitive fluorescence intensity of the cofactor flavin mononucleotide (FMN) as a function of temperature, ThermoFMN enables the identification of ligands that by interacting with the protein molecules lead to changes in protein thermostability.

Since the fluorescence of FMN cofactor is quenched by the protein environment when the protein is properly folded, the increase in FMN signal in response to temperature

elevation can be directly correlated to protein unfolding and consequent cofactor release. The melting curve, i.e., fluorescence intensity *versus* temperature, usually displays a sigmoid-like shape and changes in slope and melting temperature ( $T_m$ ), temperature where the protein is 50% unfolded, are used to provide valuable information regarding the influence of chemical environment on structural order and conformational flexibility of FMN-binding proteins.

The proposed methodology was evaluated by using the enzyme dihydroorotate dehydrogenase (DHODH) as model. DHODH is a FMN-dependent enzyme that catalyzes the oxidation of S-dihydroorotate to orotate in the fourth and only redox step in *de novo* biosynthesis of pyrimidine nucleotides.<sup>18</sup> Inhibition of dihydroorotate dehydrogenase has been considered an attractive therapeutic approach to cancer, autoimmune and parasitic diseases.<sup>13,19,20</sup> DHODH monomer shows a typical  $\alpha/\beta$  barrel fold of with a central barrel composed of eight parallel  $\beta$  strands surrounded by eight  $\alpha$ -helices. On the basis of sequence similarity, subcellular location as well as their preferences for oxidizing substrates, the DHODHs are divided in two major classes, named class 1 and class 2.<sup>21</sup> Class 1 and class 2 are structurally and mechanistically distinct, features that allow the design of class-selective inhibitors.


In the present work, human DHODH and the homologous enzymes from the protozoa parasites *Leishmania major* and *Trypanosoma cruzi* were screened against a random set of chemical factors including pH, buffer type and chemical additives. LmDHODH and TcDHODH are cytosolic enzymes, dimeric members of class 1 DHODHs and have been extensively exploited as potential drug targets against Leishmaniasis and Chagas diseases, infections found among the most neglected diseases.<sup>13,16,18,19,22,23</sup> Different to the parasitic enzymes, the human DHODH homologue, used for cross-validation assays, is a membrane-anchored mitochondrial enzyme, monomeric and member of class 2 DHODHs. In addition to the  $\alpha/\beta$  barrel, HsDHODH presents a *N*-terminal extension of approximately 40 residues that folds into two  $\alpha$ -helices connected by a short loop and plays a role in membrane anchoring.<sup>24,25</sup>

Previously to the ThermoFMN assay, the value of the fluorescence signal-to-noise ratio for sensitivity of FMN detection was estimated using free FMN as reference (Figure S1). A signal-to-noise ratio of two could be found for concentrations around 5  $\mu\text{mol L}^{-1}$ .

In fact, protein concentration of 5  $\mu\text{mol L}^{-1}$  was successfully used in our assay. However, it is important to emphasize that under a controlled experimental set up, as in our case, where the incident radiant power and path length of the cell remains unchanged; the fluorescence

signal still depends on the quantum efficiency of the FMN itself as well as on its chemical environment and solvent accessibility. Therefore, protein concentration should be considered an important parameter to be optimized during ThermoFMN assay.


The characteristic molar extinction coefficients ( $\epsilon$ ) for each protein sample were determined and protein concentration was then estimated monitoring the absorbance of protein-bound FMN as described by equation 1. As a result of different chemical environments, the height and the position of the maximum absorption peak was found to differ among DHODHs:  $\epsilon^{\text{LmDHODH}} = 11,722 \text{ mol}^{-1} \text{ L cm}^{-1}$  at 458 nm for LmDHODH,  $\epsilon^{\text{TcDHODH}} = 12,333 \text{ mol}^{-1} \text{ L cm}^{-1}$  at 460 nm for TcDHODH and  $\epsilon^{\text{HsDHODH}} = 14,259 \text{ mol}^{-1} \text{ L cm}^{-1}$  at 453 nm for HsDHODH (Figure 1).



**Figure 1.** UV/Vis absorption spectra for HsDHODH, LmDHODH and TcDHODH ( $25 \mu\text{mol L}^{-1}$ ). Chemical environment of FMN affects the peak of maximum absorbance found to be 458 nm for LmDHODH, 460 nm for TcDHODH and 453 nm for HsDHODH.

Although DHODHs were, in principle, used only as models for the development of our assay, the results obtained with ThermoFMN have provided valuable information on the characterization and screening of selective ligands for our protein targets. The single sigmoid-like curves obtained for DHODHs indicate a single melting transition state and the a sigmoidal fit allowed the determination of the characteristic melting temperatures of 49.5 °C for HsDHODH, 54.9 °C for LmDHODH and 64.2 °C for TcDHODH (Figure 2).


Structural comparison among DHODHs reveals that FMN is found non-covalently bound to the protein molecule and the short-range chemical environment of the flavin moiety is highly conserved. In fact, the prosthetic FMN group is located on the top of the barrel and stabilized by a set of conserved hydrogen bonds that involves the residues Ala<sup>20</sup>, Lys<sup>44</sup> (replaced by Gly in HsDHODH), Ser<sup>45</sup>, Asn<sup>128</sup>, Lys<sup>165</sup>, Val<sup>194</sup> (replaced by Ile in TcDHODH



**Figure 2.** Melting curves for HsDHODH, TcDHODH and LmDHODH. The sigmoidal fitting against the data was used to determine the melting temperature found as 49.5 °C, 54.9 °C and 64.2 °C for HsDHODH, LmDHODH and TcDHODH, respectively.

and Thr in LmDHODH), Asn<sup>195</sup>, Gly<sup>223</sup>, Gly<sup>251</sup>, Gly<sup>272</sup> and Thr<sup>274</sup> (Figure 3 and Figure S2). In addition, LmDHODH and TcDHODH are profoundly similar, sharing 75% of sequence identity (Figure S2) with a very similar tendency for amino acid composition and displaying on average a rmsd of 0.61 Å when superposing the Ca atoms (PDB code 3GYE and PDB code 3C3N).<sup>16,22</sup> Our analysis, together with the fact that the characteristic melting curves for LmDHODH, TcDHODH and HsDHODH display large differences in terms of absolute fluorescence, melting temperature and slope (Figure 2) indicate that differences in long-range chemical environment significantly govern the fluorescence profile of a FMN binding protein.

Unfortunately, even after very careful inspection of chemical and stereo properties of LmDHODH and TcDHODH tertiary structures, we could not provide structural basis to explain the ten degrees difference in  $T_m$  found when comparing LmDHODH and TcDHODH melting curves. Site-direct mutagenesis experiments are currently under way and will be extensively used to map



**Figure 3.** Stereoscopic three-dimensional representation of the FMN binding site. The phosphate oxygen atoms from FMN form hydrogen bonds to the main chain NH groups of Gly<sup>223</sup>, Gly<sup>251</sup>, Gly<sup>272</sup>, and Thr<sup>273</sup>. There are also hydrogen bonds between the phosphate oxygen atoms and the hydroxyl group of Thr<sup>273</sup>. The FMN ribityl hydroxyl group form hydrogen bonds with Lys<sup>165</sup>, Val<sup>195</sup>, Ala<sup>21</sup> and a water molecule. There are hydrogen bonds between the FMN isoalloxazine ring and the side chain of Lys<sup>165</sup>, Asn<sup>195</sup>, Asn<sup>128</sup>, Lys<sup>44</sup> and Ser<sup>45</sup>. The FMN isoalloxazine ring also makes hydrogen bonds to the main chain carboxyl group of Ala<sup>20</sup>.

the network of chemical interactions that contribute to enhance protein thermostability.

Stability and solubility screen were evaluated for HsDHODH, LmDHODH and TcDHODH. DHODH denaturation curves were analyzed and fitted to a sigmoid to determine the protein melting temperature for each assay. ThermoFMN proved to be compatible with the vast majority of the 96 conditions tested, including the presence of detergents, salts, chaotropic agents, known to help stabilizing and/or to reduce protein aggregation. Nevertheless, special attention should be given to acidic compounds, high concentration of reducing agents and bromide salts that showed to quench the fluorescence signal of FMN and should then be avoided.


Analysis of ThermoFMN data in terms of melting temperature and the protein-unfolding transient slope reveals that same set of seventeen compounds were found to be the best stabilizing agents for all three DHODHs tested (Figure 4): sodium phosphate monobasic monohydrate, sodium sulfate decahydrate, sodium chloride, DL-maleic acid pH 7.0, sucrose, D-sorbitol, xylitol, betaine monohydrate, methyl- $\alpha$ -D-glucopyranoside, D-(+)-trehalose dehydrate, sodium malonate, tacsimate, succinic acid, triethylamine *N*-oxide dehydrate, choline acetate and glycerol. Not surprisingly, the great majority of compounds identified fit into one of two general categories: salts and organic osmolytes, natural molecules well known for protecting cells against adverse conditions.<sup>26</sup>

In general, organic osmolytes can uniformly affect all proteins by interacting with the peptide backbone.<sup>27</sup> The ability of osmolytes to protect protein folding is due to their solvophobic effect on the peptide backbone; i.e., by disfavoring contact with the backbone, shielding it from the solvent.<sup>28</sup>

Salts have long been known to alter protein solubility.<sup>29</sup> However, the beneficial effects of salts depend on protein-specific surface charge distribution, type and concentration of the salts. At low concentrations, salts can stabilize proteins through nonspecific electrostatic interactions, dependent only on the ionic strength of the medium. At high concentrations, however, salts can exert different effects on proteins by shielding the protein with multi-ions charges. Those charges can help protein molecules interact, aggregate, and even precipitate.

In addition to shielding effects, we should not rule out the possibility that shift in melting temperatures are due to direct ligand binding to protein pockets, as already observed in the crystal structures of DHODHs in complex with glycerol,<sup>14,16,22</sup> sulfate,<sup>16</sup> and succinate molecules.<sup>30</sup> In particular, the significant improvement of thermal stability observed for malonate, malate and succinate


molecules deserves special attention due to their relative similarity with fumarate, the natural substrate for class 1A DHODHs. Kinetic and structural studies of the DHODH protein targets in presence of these substrate analogues are currently under way. Our results will contribute not only to elucidate the mechanism of action of DHODHs, but also in the identification of new chemical entities that bind to DHODH and can be used to the development of drug prototypes.



**Figure 4.** Shift in melting temperatures ( $\Delta T_m$ ) in the presence of the buffers that gave the best thermal transitions for HsDHODH (blue), LmDHODH (red) and TcDHODH (yellow).

As a prove of concept, the antiproliferative agents brequinar and teriflunomide (A771726),<sup>14,31,32</sup> both known selective inhibitors of class 2 DHODHs, had their inhibition profile evaluated by ThermoFMN assay (Figure 5). Brequinar was shown to be one of the strongest inhibitor of human DHODH with  $K_i$  values in the 5-8  $\text{nmol L}^{-1}$  range, however failed in clinical trials as anticancer and immunosuppressant agent.<sup>33</sup> A771726, the active metabolite of leflunomide (Arava), also a potent inhibitor of DHODH with an  $K_i$  value of 19  $\text{nmol L}^{-1}$  is currently used in medicine to treat autoimmune diseases such as rheumatoid arthritis or multiple sclerosis and have been investigated in treatments of cancer, virus, and parasite infections.<sup>33</sup>

Our results showed that activity in the nano molar range of brequinar and A77 1726 against HsDHODH reflected on its increased thermostability. In fact, a large positive shift in the melting temperature of  $\Delta T_m$  of 7.5 °C and 19 °C for A77 1726 and brequinar, respectively, could be observed for HsDHODH (Figure 5). On the contrary, as expected, no change in either slope or melting temperature



**Figure 5.** Effect of antiproliferative agents on thermal stability of human dihydroorotate dehydrogenase. HsDHODH in presence of 50 mmol L<sup>-1</sup> HEPES pH 7.2, 150 mmol L<sup>-1</sup> NaCl was used as the control experiment (blue line) and compared to 20 μmol L<sup>-1</sup> teriflunomide (red), 20 μmol L<sup>-1</sup> brequinar (green).

could be observed for LmDHODH and TcDHODH, data that correlate with the reported kinetic values. In addition, the correlation between binding constants and protein thermostability has been previously reported.<sup>34-37</sup> For example, the correlation between ligand binding constant (K<sub>d</sub>) and the T<sub>m</sub> has been established,<sup>34,35</sup> where K<sub>d</sub> has been calculated using ThermoFluor assays by varying the ligand concentration and using the constant of protein unfolding and protein concentration.<sup>36,37</sup> Additionally, the K<sub>d</sub> determination of tightly bound ligands (< 10 nM), which is poorly achieved by isothermal titration calorimetry (ITC), have already been precisely resolved by thermal shift assays.<sup>36</sup> The characterization of enzyme inhibition mechanisms has also been accomplished by comparing the thermal shift of proteins in the presence of substrate with varying concentrations of inhibitors of interest.<sup>38</sup> Furthermore, insights on ligand potency and selectivity can also be obtained.<sup>35</sup> This arises since protein stabilization can occur through ligand binding at a site not linked to enzyme activity.

Altogether, those results support the idea that this reference methodology is not only effective on identifying ligands but can also provide insights on their potency and selectivity, features that are crucial for cross-validation assays.

## Conclusion

FMN-containing and FAD-containing enzymes correspond to the large group of flavoproteins found in archaea, bacteria, and eukaryotes and involved in the regulation of many fundamental cellular processes.<sup>39</sup> Thus, enzymes that utilize the redox-active isoalloxazine ring system (FMN and FAD) as coenzymes constitute an important group of proteins to be characterized and

explored as drug targets; knowledge that could result in new strategies to tackle chronic diseases.

In this study we described the development of ThermoFMN assay, an alternative dye-free methodology for the conventional ThermoFluor technique.<sup>5</sup> ThermoFMN exploits the presence of FMN flavin group as the fluorescence probe that can be used for monitoring effects of ligand binding on unfolding temperature of FMN-binding proteins. The thermal information gained by investigation of the protein stability under different buffer compositions can be effectively used to guide purification, biophysical characterization and identification of ligands to be used as prototypes for drug development.

ThermoFMN assay supports the use of a single filter pair optimized for excitation and emission of SYBR Green I (with excitation maxima at 492 and emission spectra at 516 nm, respectively), and display excellent sensitivity with minimum amounts of protein samples.

ThermoFMN assay was evaluated against the enzymes dihydroorotate dehydrogenase from *Leishmania major*, *Trypanosoma cruzi* and *Homo sapiens*. The characteristic melting curves for LmDHODH, TcDHODH and HsDHODH showed to be highly reproducible and the monitoring of melting temperatures ( $\Delta T_m$ ) against a random set of buffers and additives demonstrated a large compatibility with the majority of the chemical compounds tested.

In addition, our assays against the antiproliferative agents, brequinar and teriflunomide,<sup>14</sup> known DHODH inhibitors, demonstrated that ThermoFMN assay can also be used to determine ligand selectivity, very useful for cross-validation assays.

In summary, the low cost, fast, simplicity, low sample-consuming and the general applicability of ThermoFMN, make this technique attractive for identification of positive hits of FMN-binding proteins and constitute a new tool to be extensively used in the process of development of new therapies against neglected diseases.

## Supplementary Information

Supplementary data are available free of charge at <http://jbcs.sbq.org.br> as PDF file.

## Acknowledgments

We would like to thank Prof Jon Clardy from Harvard Medical School for providing us with the DNA construct used to subclone human DHODH.

Funding was provided by FAPESP (Fundação de Amparo à Pesquisa do Estado de São Paulo), grants 2012/25075-0 (MCN), 2008/11644-8 (RAPP), 2011/14269-6 (GPT),

2011/23504-9 (RGR), 2007/08703-0 (MPP) and CNPq (Conselho Nacional de Pesquisa), grant 159061/2012-1 (VCS).

## References

- d'Alessandro, E. D. L.; Giraldo, G.; *Clin. Ter.* **2011**, *162*, E93.
- Marchal, B.; Van Dormael, M.; Pirard, M.; Cavalli, A.; Kegels, G.; Polman, K.; *Acta Trop.* **2011**, *120*, S177.
- Gilbert, I. H.; *J. Med. Chem.* **2013**, *56*, 7719.
- Renslo, A. R.; McKerrow, J. H.; *Nat. Chem. Biol.* **2006**, *2*, 701.
- Pantoliano, M. W.; Petrella, E. C.; Kwasnoski, J. D.; Lobanov, V. S.; Myslik, J.; Graf, E.; Carver, T.; Asel, E.; Springer, B. A.; Lane, P.; Salemme, F. R.; *J. Biomol. Screening* **2001**, *6*, 429.
- Seabrook, S. A.; Newman, J.; *ACS Comb. Sci.* **2013**, *15*, 387.
- Shi, S.; Semple, A.; Cheung, J.; Shameem, M.; *J. Pharm. Sci.* **2013**, *102*, 2471; Reinhard, L.; Mayerhofer, H.; Geerlof, A.; Mueller-Dieckmann, J.; Weiss, M. S.; *Acta Crystallogr., Sect. F: Struct. Biol. Cryst. Commun.* **2013**, *69*, 209.
- Ruvinov, S. B.; Yang, X. J.; Parris, K. D.; Banik, U.; Ahmed, S. A.; Miles, E. W.; Sackett, D. L.; *J. Biol. Chem.* **1995**, *270*, 6357.
- Alexandrov, A. I.; Mileni, M.; Chien, E. Y. T.; Hanson, M. A.; Stevens, R. C.; *Structure* **2008**, *16*, 351.
- Warne, T.; Serrano-Vega, M. J.; Tate, C. G.; Schertler, G. F. X.; *Protein Express. Purif.* **2009**, *65*, 204.
- Fornieris, F.; Orru, R.; Bonivento, D.; Chiarelli, L. R.; Mattevi, A.; *FEBS J.* **2009**, *276*, 2833.
- Joosten, V.; van Berkel, W. J. H.; *Curr. Opin. Chem. Biol.* **2007**, *11*, 195.
- Pinheiro, M. P.; Emery, F. S.; Nonato, M. C.; *Curr. Pharm. Des.* **2013**, *19*, 2615.
- Liu, S. P.; Neidhardt, E. A.; Grossman, T. H.; Ocain, T.; Clardy, J.; *Structure Fold Des.* **2000**, *8*, 25.
- Feliciano, P. R.; Cordeiro, A. T.; Costa, A. J.; Nonato, M. C.; *Protein Expression Purif.* **2006**, *48*, 98.
- Pinheiro, M. P.; Iulek, J.; Nonato, M. C.; *Biochem. Biophys. Res. Commun.* **2008**, *369*, 812.
- Niesen, F. H.; Berglund, H.; Vedadi, M.; *Nat. Protoc.* **2007**, *2*, 2212.
- Nonato, M. C.; Costa-Filho, A. J. In *The Dihydroorotate Dehydrogenases*; Hille, R.; Miller, S.; Palfey, B., eds.; de Gruyter: Berlin, Germany, 2013, ch. 14.
- Vyas, V. K.; Ghate, M.; *Mini-Rev. Med. Chem.* **2011**, *11*, 1039.
- Baumann, P.; Mandl-Weber, S.; Voelkl, A.; Adam, C.; Bumeder, I.; Oduncu, F.; Schmidmaier, R.; *Mol. Cancer Ther.* **2009**, *8*, 366.
- Jones, M. E.; *Annu. Rev. Biochem.* **1980**, *49*, 253.
- Cordeiro, A. T.; Feliciano, P. R.; Pinheiro, M. P.; Nonato, M. C.; *Biochimie* **2012**, *94*, 1739.
- Cheleski, J.; Rocha, J. R.; Pinheiro, M. P.; Wiggers, H. J.; da Silva, A. B. F.; Nonato, M. C.; Montanari, C. A.; *Eur. J. Med. Chem.* **2010**, *45*, 5899.
- Couto, S. G.; Nonato, M. C.; Costa-Filho, A. J.; *Biochem. Biophys. Res. Commun.* **2011**, *414*, 487.
- Couto, S. G.; Nonato, M. C.; Costa-Filho, A. J.; *Biophys. J.* **2008**, *94*, 1746.
- Harries, D.; Rosgen, J. In *Biophysical Tools for Biologists*; Correia, J. J.; Detrich, H. W., eds.; Elsevier: Oxford, UK, 2008, ch. 22.
- Bolen, D. W.; Baskakov, I. V.; *J. Mol. Biol.* **2001**, *310*, 955.
- Ishibashi, M.; Sakashita, K.; Tokunaga, H.; Arakawa, T.; Tokunaga, M.; *J. Protein Chem.* **2003**, *22*, 345.
- Hamada, H.; Arakawa, T.; Shiraki, K.; *Curr. Pharm. Biotechnol.* **2009**, *10*, 400.
- Inaoka, D. K.; Sakamoto, K.; Shimizu, H.; Shiba, T.; Kurisu, G.; Nara, T.; Aoki, T.; Kita, K.; Harada, S.; *Biochemistry* **2008**, *47*, 10881.
- Chen, S. F.; Perrella, F. W.; Behrens, D. L.; Papp, L. M.; *Cancer Res.* **1992**, *52*, 3521.
- Davis, J. P.; Cain, G. A.; Pitts, W. J.; Magolda, R. L.; Copeland, R. A.; *Biochemistry* **1996**, *35*, 1270.
- Munier-Lehmann, H.; Vidalain, P.-O.; Tangy, F.; Janin, Y. L.; *J. Med. Chem.* **2013**, *56*, 3148.
- Celej, M. S.; Montich, C. G.; Fidelio, G. D.; *Protein Sci.* **2003**, *12*, 1496.
- Bullock, A. N.; Debreczeni, J. E.; Fedorov, O. Y.; Nelson, A.; Marsden, B. D.; Knapp, S.; *J. Med. Chem.* **2005**, *48*, 7604.
- Zubriene, A.; Matuliene, J.; Baranauskienė, L.; Jachno, J.; Torresan, J.; Michailovienė, V.; Cimperman, P.; Matulis, D.; *Int. J. Mol. Sci.* **2009**, *10*, 2662.
- Matulis, D.; Kranz, J. K.; Salemme, F. R.; Todd, M. J.; *Biochemistry* **2005**, *44*, 5258.
- Lea, W. A.; Simeonov, A.; *PLoS One* **2012**, *7*, (4): e36219.
- Macheroux, P.; Kappes, B.; Ealick, S. E.; *FEBS J.* **2011**, *278*, 2625.

Submitted on: March 20, 2014

Published online: July 1, 2014

FAPESP has sponsored the publication of this article.